255 related articles for article (PubMed ID: 16842630)
1. The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway.
Vetter I; Wyse BD; Monteith GR; Roberts-Thomson SJ; Cabot PJ
Mol Pain; 2006 Jul; 2():22. PubMed ID: 16842630
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms involved in potentiation of transient receptor potential vanilloid 1 responses by ethanol.
Vetter I; Wyse BD; Roberts-Thomson SJ; Monteith GR; Cabot PJ
Eur J Pain; 2008 May; 12(4):441-54. PubMed ID: 17826200
[TBL] [Abstract][Full Text] [Related]
3. Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain.
Endres-Becker J; Heppenstall PA; Mousa SA; Labuz D; Oksche A; Schäfer M; Stein C; Zöllner C
Mol Pharmacol; 2007 Jan; 71(1):12-8. PubMed ID: 17005903
[TBL] [Abstract][Full Text] [Related]
4. Relative roles of protein kinase A and protein kinase C in modulation of transient receptor potential vanilloid type 1 receptor responsiveness in rat sensory neurons in vitro and peripheral nociceptors in vivo.
Varga A; Bölcskei K; Szöke E; Almási R; Czéh G; Szolcsányi J; Pethö G
Neuroscience; 2006 Jun; 140(2):645-57. PubMed ID: 16564637
[TBL] [Abstract][Full Text] [Related]
5. Rapid, opioid-sensitive mechanisms involved in transient receptor potential vanilloid 1 sensitization.
Vetter I; Cheng W; Peiris M; Wyse BD; Roberts-Thomson SJ; Zheng J; Monteith GR; Cabot PJ
J Biol Chem; 2008 Jul; 283(28):19540-50. PubMed ID: 18482991
[TBL] [Abstract][Full Text] [Related]
6. Opioid withdrawal increases transient receptor potential vanilloid 1 activity in a protein kinase A-dependent manner.
Spahn V; Fischer O; Endres-Becker J; Schäfer M; Stein C; Zöllner C
Pain; 2013 Apr; 154(4):598-608. PubMed ID: 23398938
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase A maintains cellular tolerance to mu opioid receptor agonists in hypothalamic neurosecretory cells with chronic morphine treatment: convergence on a common pathway with estrogen in modulating mu opioid receptor/effector coupling.
Wagner EJ; Rønnekleiv OK; Kelly MJ
J Pharmacol Exp Ther; 1998 Jun; 285(3):1266-73. PubMed ID: 9618432
[TBL] [Abstract][Full Text] [Related]
8. Cloning and pharmacological characterization of mouse TRPV1.
Correll CC; Phelps PT; Anthes JC; Umland S; Greenfeder S
Neurosci Lett; 2004 Nov; 370(1):55-60. PubMed ID: 15489017
[TBL] [Abstract][Full Text] [Related]
9. Modulation of transient receptor vanilloid 1 activity by transient receptor potential ankyrin 1.
Spahn V; Stein C; Zöllner C
Mol Pharmacol; 2014 Feb; 85(2):335-44. PubMed ID: 24275229
[TBL] [Abstract][Full Text] [Related]
10. Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia.
Maione S; Starowicz K; Cristino L; Guida F; Palazzo E; Luongo L; Rossi F; Marabese I; de Novellis V; Di Marzo V
J Neurophysiol; 2009 May; 101(5):2411-22. PubMed ID: 19297510
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.
Bao Y; Gao Y; Yang L; Kong X; Yu J; Hou W; Hua B
Channels (Austin); 2015; 9(5):235-43. PubMed ID: 26176938
[TBL] [Abstract][Full Text] [Related]
12. Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C.
Plant TD; Zöllner C; Kepura F; Mousa SS; Eichhorst J; Schaefer M; Furkert J; Stein C; Oksche A
Mol Pain; 2007 Nov; 3():35. PubMed ID: 18001466
[TBL] [Abstract][Full Text] [Related]
13. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
14. Adenylate cyclase/cAMP/protein kinase A signaling pathway inhibits endothelin type A receptor-operated Ca²⁺ entry mediated via transient receptor potential canonical 6 channels.
Horinouchi T; Higa T; Aoyagi H; Nishiya T; Terada K; Miwa S
J Pharmacol Exp Ther; 2012 Jan; 340(1):143-51. PubMed ID: 22001259
[TBL] [Abstract][Full Text] [Related]
15. Engagement of signaling pathways of protease-activated receptor 2 and μ-opioid receptor in bone cancer pain and morphine tolerance.
Bao Y; Gao Y; Hou W; Yang L; Kong X; Zheng H; Li C; Hua B
Int J Cancer; 2015 Sep; 137(6):1475-83. PubMed ID: 25708385
[TBL] [Abstract][Full Text] [Related]
16. Contribution of transient receptor potential vanilloid subfamily 1 to endothelin-1-induced thermal hyperalgesia.
Kawamata T; Ji W; Yamamoto J; Niiyama Y; Furuse S; Namiki A
Neuroscience; 2008 Jun; 154(3):1067-76. PubMed ID: 18495351
[TBL] [Abstract][Full Text] [Related]
17. Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway.
Mohapatra DP; Nau C
J Biol Chem; 2003 Dec; 278(50):50080-90. PubMed ID: 14506258
[TBL] [Abstract][Full Text] [Related]
18. Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-mediated phosphorylation at S800.
Mandadi S; Tominaga T; Numazaki M; Murayama N; Saito N; Armati PJ; Roufogalis BD; Tominaga M
Pain; 2006 Jul; 123(1-2):106-16. PubMed ID: 16564619
[TBL] [Abstract][Full Text] [Related]
19. Role of cAMP-dependent protein kinase (PKA) in opioid agonist-induced mu-opioid receptor downregulation and tolerance in mice.
Shen J; Benedict Gomes A; Gallagher A; Stafford K; Yoburn BC
Synapse; 2000 Dec; 38(3):322-7. PubMed ID: 11020235
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice.
Amadesi S; Cottrell GS; Divino L; Chapman K; Grady EF; Bautista F; Karanjia R; Barajas-Lopez C; Vanner S; Vergnolle N; Bunnett NW
J Physiol; 2006 Sep; 575(Pt 2):555-71. PubMed ID: 16793902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
